Geographic Atrophy of the Macula Clinical Trials in Hagerstown, Maryland

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD